Biomimetic M1 macrophage Membrane–Modified liposomes Co-delivering ponatinib and ginsenoside Rg3 for inhibition of breast cancer lung metastasis
- 1Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
Abstract
Background: Breast cancer ranks among the most prevalent malignant tumors in women worldwide, with lung metastasis accounting for over 90% of fatalities. Despite this high mortality, effective targeted therapies remain insufficient. Although ponatinib (PNT) shows potential for treating breast cancer lung metastasis (BCLM), its delivery requires optimization. This study aims to construct a biomimetic nanomedicine for targeted delivery of PNT, thereby efficiently treating BCLM. Methods: Ginsenoside Rg3 (Rg3) can serve as a substitute for cholesterol as a membrane support material while also acting as an adjuvant in cancer treatment. We replaced cholesterol with Rg3 to prepare PNT-Rg3-Lipo liposomes, extracted the cell membrane of M1 macrophages to coat it on the surface of PNT-Rg3-Lipo, and obtained biomimetic nano MM/PNT-Rg3-Lipo. The characterization of biomimetic nanomedicines was conducted, and the functionality of biomimetic nanomedicines was evaluated at both animal and cellular levels. Results: The macrophage membrane-modified MM/PNT-Rg3-Lipo retains most proteins found on M1-type macrophages, including the characteristic proteins integrin α4 and β1. This macrophage membrane-modified MM/PNT-Rg3-Lipo reduces macrophage phagocytosis, while enhancing uptake by metastatic breast cancer cells. In vitro , macrophage membrane-modified MM/PNT-Rg3-Lipo exhibits a stronger cytotoxic effect on breast cancer cells compared to free PNT. In vivo , MM/PNT-Rg3-Lipo shows a lower hemolysis rate, demonstrating its safety. Macrophage membrane modification guides liposomes to lung metastatic sites, leading to localized drug release and consequential inhibition of breast cancer lung metastases. Conclusion: The biomimetic macrophage membrane-coated liposomes, MM/PNT-Rg3-Lipo, which we have innovatively prepared, exhibit promising therapeutic effects against breast cancer lung metastases.
Related
- Targeted delivery of celastrol and siRNA via macrophage biomimetic nanoparticles for doxorubicin-induced cardiomyopathy therapy
- Microenvironmental-Regulated Chondroitin Sulfate Nanomicelles for Inhibition of Breast Cancer Drug Resistance and Metastasis
- Targeting histone methylation with ROS nanoparticles delivering PARPi prodrugs to amplify the stimulation of cGAS-STING for immunotherapy in ovarian cancer
- Small-Strain Tensile Characterization and Finite Element Calibration of Sodium Alginate-Based Biomimetic Artificial Muscle Strips
- A biomimetic bilayered vascular graft integrating electrospun polyurethane and gelatin/elastin hydrogel achieves arterial-like compliance and enhanced endothelialization
BibTeX
@article{quan2026biomimetic,
title = {{Biomimetic M1 macrophage Membrane–Modified liposomes Co-delivering ponatinib and ginsenoside Rg3 for inhibition of breast cancer lung metastasis}},
author = {Lei Quan and Yue Gao and Chen Zhang and Yue Ding and Sijuan Sun and Xinran Tai and Qingqing Yu and Dong Wang and Yumei Wang},
journal = {Journal of Ginseng Research},
year = {2026},
month = jul,
doi = {10.1016/j.jgr.2026.101110},
url = {https://doi.org/10.1016/j.jgr.2026.101110},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Biomimetic M1 macrophage Membrane–Modified liposomes Co-delivering ponatinib and ginsenoside Rg3 for inhibition of breast cancer lung metastasis
AU - Lei Quan
AU - Yue Gao
AU - Chen Zhang
AU - Yue Ding
AU - Sijuan Sun
AU - Xinran Tai
AU - Qingqing Yu
AU - Dong Wang
AU - Yumei Wang
PY - 2026
DA - 2026/07/10
JO - Journal of Ginseng Research
DO - 10.1016/j.jgr.2026.101110
UR - https://doi.org/10.1016/j.jgr.2026.101110
AB - Background: Breast cancer ranks among the most prevalent malignant tumors in women worldwide, with lung metastasis accounting for over 90% of fatalities. Despite this high mortality, effective targeted therapies remain insufficient. Although ponatinib (PNT) shows potential for treating breast cancer lung metastasis (BCLM), its delivery requires optimization. This study aims to construct a biomimetic nanomedicine for targeted delivery of PNT, thereby efficiently treating BCLM. Methods: Ginsenoside Rg3 (Rg3) can serve as a substitute for cholesterol as a membrane support material while also acting as an adjuvant in cancer treatment. We replaced cholesterol with Rg3 to prepare PNT-Rg3-Lipo liposomes, extracted the cell membrane of M1 macrophages to coat it on the surface of PNT-Rg3-Lipo, and obtained biomimetic nano MM/PNT-Rg3-Lipo. The characterization of biomimetic nanomedicines was conducted, and the functionality of biomimetic nanomedicines was evaluated at both animal and cellular levels. Results: The macrophage membrane-modified MM/PNT-Rg3-Lipo retains most proteins found on M1-type macrophages, including the characteristic proteins integrin α4 and β1. This macrophage membrane-modified MM/PNT-Rg3-Lipo reduces macrophage phagocytosis, while enhancing uptake by metastatic breast cancer cells. In vitro , macrophage membrane-modified MM/PNT-Rg3-Lipo exhibits a stronger cytotoxic effect on breast cancer cells compared to free PNT. In vivo , MM/PNT-Rg3-Lipo shows a lower hemolysis rate, demonstrating its safety. Macrophage membrane modification guides liposomes to lung metastatic sites, leading to localized drug release and consequential inhibition of breast cancer lung metastases. Conclusion: The biomimetic macrophage membrane-coated liposomes, MM/PNT-Rg3-Lipo, which we have innovatively prepared, exhibit promising therapeutic effects against breast cancer lung metastases.
SN - 1226-8453
SN - 2093-4947
ER -